BPC-157

What it is

BPC-157 — short for Body Protection Compound 157 — is a synthetic 15-amino-acid peptide derived from a partial sequence of a protein found naturally in human gastric juice. It is stable in gastric acid and remains active even after oral administration in animal models, which is unusual for peptides. The compound does not occur as a free-standing protein in the body; it was isolated, sequenced, and synthesized by Predrag Sikiric and colleagues at the University of Zagreb, Croatia, who have driven the majority of BPC-157 research over the past three decades. Because it can be administered orally, by injection (subcutaneous or intramuscular), or applied topically, it has attracted wide interest both in academic circles and — controversially — among athletes and biohackers seeking faster recovery from injury. Unlike many research peptides it has reached Phase II clinical trials for inflammatory bowel disease, though published results from those trials are limited.

How it works

BPC-157 acts through several overlapping mechanisms rather than a single clean pathway, which helps explain why it has been reported to affect so many tissue types. The most well-characterised mechanism involves the nitric oxide (NO) system: BPC-157 modulates endothelial nitric oxide synthase (eNOS) and influences NO production in a context-dependent way, promoting protective effects on blood vessels and gut mucosa while blunting the cytotoxic overproduction of NO that occurs in injury states.

A second key mechanism is pro-angiogenic signalling. BPC-157 upregulates vascular endothelial growth factor receptor 2 (VEGFR2) expression on endothelial cells, promotes VEGFR2 internalisation, and activates the downstream VEGFR2–Akt–eNOS axis. The result is increased vessel sprouting and improved blood supply to injured tissue — important for healing tendons and ligaments, which have notoriously poor vascularity.

At the cellular level, BPC-157 activates focal adhesion kinase (FAK) and paxillin signalling in fibroblasts, directly accelerating the migration of tendon and skin fibroblasts into wound sites. It also promotes expression of growth hormone receptor (GHR) in tendon fibroblasts, potentially amplifying the anabolic effects of endogenous GH on connective tissue. In the gastrointestinal tract, BPC-157 enhances mucosal integrity, reduces oxidative stress, and appears to interact with the dopaminergic and serotonergic systems, which may partly explain reported effects on mood and neuroprotection in animal models. The downstream signalling converges on a reduction in inflammation and an acceleration of organised tissue remodelling, without the immunosuppressive side effects of corticosteroids.

What the research shows

The published literature on BPC-157 is extensive but almost entirely preclinical — rats and mice, with some cell-culture work. The same Zagreb research group has authored the large majority of these studies. Below are representative findings across the key areas of investigation.

Safety and limitations

In animal studies, BPC-157 has a consistently clean acute safety profile: no reported lethal dose has been established in rodents even at very high doses, no organ toxicity has been observed, and it does not appear to suppress the hypothalamic–pituitary–adrenal axis. These are genuinely reassuring signals from preclinical work.

However, the gap between animal data and human safety is substantial for any peptide. BPC-157 has been tested in Phase II clinical trials for ulcerative colitis (under the trade designations PL 14736 and PL-10 by Pliva, Croatia), but detailed peer-reviewed efficacy results from these trials have not been published in the open literature. No large-scale, peer-reviewed randomised controlled trial in humans has been completed or published as of early 2026.

Long-term effects — particularly around angiogenesis stimulation — are unknown in humans. Upregulating VEGFR2 and promoting vessel growth could theoretically accelerate tumour vascularisation in individuals with occult malignancies, though this has not been studied. The overwhelming dominance of a single research group in the literature also raises the question of independent replication.

From a regulatory standpoint, BPC-157 is not approved as a drug or supplement anywhere in the world. The World Anti-Doping Agency (WADA) added it to the Prohibited List in 2022, reflecting both its performance-enhancing potential and the lack of safety data in humans. Anyone consuming it — via grey-market injection kits or compounded preparations — is doing so without regulatory oversight, quality control, or informed consent based on human evidence.

Sources